Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lmao keep trying it proves my point
YOU ARE SO TRANSPARENT...OTC BOY!!
Like I said so much free room in there
Work on that jealousy issue
YOU FOLLOW SOMEONE AND JUST REPEAT WHAT YOU READ ON BOARDS..
All that real estate in your head I have for free
TICKER CALLER...THATS ALL U DO!
i KNOW ITS ONE OF YOUR 300% RUNNERS...LMAO..YOU ARE A JOKE
Really doh
Yep , it appears so , great to have gotten in on the dip yesterday . fast approaching shares floating on this trading ,amazing.
AMRS, to be delisted next week. Pump and dump before delisting.
Agree BK always spikes
AMRS, 365 Million shares (o/s) dumping before delisting after filing Bankruptvcy.
Not late at all
You tooo late .08 gone forever
$AMRS - 👆Up 48% Pre-Market/Current Price $0.097
👉Announces Operational & Financial Restructuring to Advance Strategic Transformation
👉Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan
👉$190m Financing Commitment from Foris Ventures
I'm out! Nice 2 day gain.
It appears that Amyris bought 49% more of a joint venture, Aprinnova, LLC, of which they now own 99%. Seems a good move but not a needle mover, imo.
https://www.sec.gov/edgar/browse/?CIK=1365916&owner=exclude
https://aprinnova.com/
So.....does anyone have any idea why AMRS went up almost 20% today and on significantly more volume?
Was last Thursday's big spike up for about 30 minutes a quick short squeeze, an options expiration play, or somebody accumulating a lot, too quickly, in anticipation of good news? Volume has been high for a few days, and "volume precedes price," at least often, but price remains about where it was after recovery a few weeks ago from seven month slump. I have little new info on the company.
Do you know what Amyris is? It is a small bushy tree with compound leaves and white flowers which grows wild in thickets all over the island of Haiti.
I listened to the call. I liked what I heard. Other than not making a profit right now, I saw no downside at these prices. The future looks good. The new plant is almost on line and their strategy is coming together. I'm fortunate I found out now rather than a while back at a much higher price. Almost everything else I have, other than CDMO is under water. I seem to like a company too early. I got my toe wet here.
I read the earnings report this morning. Perhaps buyers are belatedly enthusiastic about the remainder of the year. The update about Purecane introduction to Walmart stores was interesting. Melo also briefly discussed additional revenue from 2 additional molecules amounting to potential $100-125k/molecule by end of year. Vanilla and vitamin E market remain stable. Brazil fermentation factory was also discussed. I would appreciate your reaction to the report.
Is there any reason for our large upswing or was it just so over sold that we just couldn't help loading up?
Very interesting video. Amyris has very interesting future I believe with this manufacturing capacity to create high value molecules demanded by customers. Started to add again.
EMERYVILLE, Calif., April 11, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-Market(TM) technology platform today announced that it has started the commissioning of its new fermentation plant in Barra Bonita, Brazil.
AMRS started commissioning its new fermentation plant in Brazil today. Details below:
https://investorshub.advfn.com/Amyris-Inc-AMRS-20449
"....The greenfield site at Barra Bonita is a strategic investment with which Amyris leads the biotechnology sector with manufacturing at industrial scale. The new plant is strategically located next to the Raizen sugar mill, which is the world's second largest of its kind, ensuring continuity of supply and favorable feedstock economics. Sugar cane is a key feedstock for producing our sustainable ingredients. Brazil ranks number one in global sugar production, and operating costs in Brazil are advantaged compared to the U.S. and Europe. The fermentation plant has a proprietary design with a process tower that is 2-times taller than the company's prior Brotas plant to take full advantage of gravity in its vertical fermentation process. The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products. The site has ample space and infrastructure for future expansion.
There is strong consumer demand for bio-based products. A real shift is occurring across multiple end-markets, including food and personal care. Biotechnology has seen significant investment over the past years. However, the majority of the funding has been applied toward the front of the funnel; gene discovery, genetic pathway modeling and microbe engineering. Little investment has been seen downstream in fermentation process development, scale up and fermentation at scale. The lack of scaled precision fermentation expertise and capacity, and thus the ability to manufacture cost effectively at scale is an impediment to biotechnology making a commercial impact. The sector's capital light approach toward fermentation capacity does not bode well for future success.
"At Amyris we are taking control of our destiny with the Barra Bonita plant," said John Melo, President and Chief Executive Officer. "Industry experts are seeing a significant future gap between supply and demand of fermentation-based products. We set out a strategic path over a decade ago that, beyond being the recognized leaders in the science of biotechnology, we would invest in fermentation process capability and capacity. We have a highly experienced team that combines the art and science of manufacturing at scale all the way from the lab bench to the fermentation tower. We are very proud of the team that has engineered and constructed our new plant in record time and during an unprecedented pandemic. We have started to activate the process control modules and are in the process of testing the instruments and automation protocols to ensure that all systems and components are operating efficiently and safely. We are looking forward to accelerating the commissioning process, including the completion of the sterility hold, with a view to operationalize the plant during the second quarter.".....
I sold all my cdmo over 30. I've been loading up here from six down to the threes. 3 to 30 was a hell of a gain on cdmo.
There's no doubt we can do the same thing here. Everything is just been put in place to substantially increase margins. We are now selling squalene for $2500 a kilo instead of 50 bucks a kilo. The margin problem is over and we're ahead of schedule and production of several new products. The quality of the products is excellent all that is needed now is to build the brands. That's not going to be difficult because of the quality of the merchandise.
I see clear sailing and at least 38 million shorts that should cover. The rise should be consistent.
I'd say 60 to 90 days to 10.
Barrons loved this stock at $15.25....hmm how about at under $5?
Once again, the old adage of "do your own research" is very prudent....also, being loved by a high profile financial publication is no guarantee of stock market gains...quite the opposite in this case.
The company has some great technology and now a solid financing package, but they have to quit burning through cash....it is time for proper business execution which means streamlining production and review pricing to ensure the company starts making solid margins and profitability.
They are close, but not sure if this management team has it figured out yet!
https://ih.advfn.com/stock-market/NASDAQ/amyris-AMRS/stock-news/86925212/amyris-and-immunitybio-complete-joint-venture-for
"EMERYVILLE, Calif. and CULVER CITY, Calif., Jan. 3, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, and ImmunityBio (Nasdaq: IBRX), a clinical-stage immunotherapy company, today announced the completion of a previously announced joint venture agreement to accelerate the commercialization of a leading next-generation COVID-19 vaccine.
IB Logo
Amyris and ImmunityBio combine important vaccine technology and manufacturing capabilities in the joint venture. Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second generation vaccine in 2022 as soon as is practically possible with a goal of delivering immunity for COVID-19 and access to underserved parts of the world where current vaccine technology is challenged due to cost and supply chain limitations.
"We are pleased to combine our expertise in human trials, T-Cell technology and our access to RNA manufacturing capacity with the Amyris and Infectious Disease Research Institute (IDRI) RNA technology platform and Amyris' adjuvant technology," said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. "Combined we have a real opportunity to provide true immunity against COVID-19 variants along with a platform that can quickly adapt to a future potential respiratory virus. We are focused on completing human trials and delivering vaccines in 2022."
"Combining our RNA technology with ImmunityBio's expertise and access has the potential to significantly accelerate and de-risk our time to market for a much-needed second generation COVID-19 vaccine," said John Melo, President and Chief Executive Officer of Amyris. "We are very pleased with the progress our teams have made in the short time we've been working together and remain focused on completing successful human trials as quickly as possible."
"Two years into the COVID-19 pandemic, it has become abundantly clear that next-generation vaccines will be required to put the pandemic behind us," said Corey Casper, M.D., MPH and Chief Executive Officer of IDRI. "Vaccines that are accessible to every person across the globe, broad in their protection against current and future variants of concern, and invoke durable protective immunity are now within our reach. The ability to 'mix and match' vaccine platforms through this new joint venture and ImmunityBio's multiple COVID vaccine platforms represents one of the most exciting approaches to ending COVID-19."
Further announcements will be made when results of human trials are available."
https://ih.advfn.com/stock-market/NASDAQ/amyris-AMRS/stock-news/86883779/amyris-and-minerva-foods-complete-joint-venture-an
"EMERYVILLE, Calif., Dec. 23, 2021 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS) ("Amyris"), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumption through its Lab-to-MarketTM operating platform, today announced the completion of a previously announced joint venture agreement with MF 92 VENTURES LLC ("Minerva"), a Minerva Foods subsidiary, to develop molecules for the sustainable production and distribution of animal protein ("the Joint Venture").
The Joint Venture between Amyris and Minerva will be focused on enhancing the sustainability of the Brazilian meat exporting market, which is the largest in the world. Minerva and Amyris will collaborate on the development, scale-up and production of new target molecules, which Minerva will fund and bring to market commercially. The new molecules will target several sustainability objectives, including improving and lowering the carbon intensity of producing animal protein; sustainable packaging; and fermentation-based, natural preservatives that facilitate the transport of meat around the world. Additionally, the parties expect to work on the production of fermentation-based protein as an alternative to animal-based protein.
Relevant regulatory approvals have been attained for the development and scale-up of a vertical technology and commercialization platform that aims to transform the way protein is produced. The Joint Venture is expected to generate first license revenue for Amyris before the end of 2021 and deliver first commercial production of its initial targets in 2022.
"We are very pleased to partner with Amyris, the leader in synthetic biotechnology and the world's leading fermentation technology company," said Fernando Galletti De Queiroz, Chief Executive Officer of Minerva. "We have a strong track record of commercializing innovative technologies for producing animal protein and reducing carbon emissions. With Amyris' clean fermentation technology, we expect to lead the disruption of the animal protein industry and reduce our industry's carbon footprint."
"We are excited to further expand the reach of our technology and manufacturing expertise through our partnership with Minerva Foods. We believe this collaboration will accelerate the commercialization of natural, sustainably produced molecules that are capable of transforming the production and supply chain of animal protein," commented John Melo, President and Chief Executive Officer of Amyris. "We have a proven track record in biotechnology of developing and scaling molecules that are transforming several vertical markets. We are executing well and are on track for a strong fourth quarter."[more]
$AMRS Watching Amyris, Akoustis Technologies, Gevo; Traders Circulate TipRanks Article '3 "Strong Buy" Stocks Under $10 That Are Poised for a Breakout Year'
https://www.tipranks.com/news/article/3-strong-buy-stocks-under-10-that-are-poised-for-a-breakout-year/
The CEO should be fired!
Just no excuse for his incompetence.
The institutional investors must be pissed. There was a lot of them. Maybe they are all gone now.
Followers
|
108
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4221
|
Created
|
03/08/11
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |